Cargando…

Effect of Modified Vaccinia Ankara–5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial

IMPORTANCE: The success of immunotherapy with checkpoint inhibitors is not replicated in most cases of colorectal cancer; therefore, different strategies are urgently required. The oncofetal antigen 5T4 is expressed in more than 90% of cases of metastatic colorectal cancer (mCRC). Preliminary data u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scurr, Martin, Pembroke, Tom, Bloom, Anja, Roberts, David, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard, Brewster, Alison, Jones, Robert, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Wright, Melissa, Hills, Robert, Gallimore, Awen, Godkin, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824319/ https://www.ncbi.nlm.nih.gov/pubmed/28880972 http://dx.doi.org/10.1001/jamaoncol.2017.2579

Ejemplares similares

T‐cell modulation by cyclophosphamide for tumour therapy
por: Hughes, Ellyn, et al.
Publicado: (2018)

Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver
por: Pembroke, Tom, et al.
Publicado: (2015)

High endothelial venules: Help or hindrance in the quest for antitumor immunity?
por: Gallimore, Awen, et al.
Publicado: (2013)

The paradox of NKp46(+) natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment
por: Pembroke, Tom, et al.
Publicado: (2014)

Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells
por: Thomson, Amanda, et al.
Publicado: (2021)

Hunting for clues: Regulatory T cells and colorectal cancer
por: Gallimore, Awen, et al.
Publicado: (2012)

Assessing the Prognostic Value of Preoperative Carcinoembryonic Antigen-Specific T-Cell Responses in Colorectal Cancer
por: Scurr, Martin J., et al.
Publicado: (2015)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
por: Tenesaca, Shirley, et al.
Publicado: (2021)

Progression of carcinogen‐induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cells via blood vessels and lymphatics
por: Ondondo, Beatrice, et al.
Publicado: (2013)

Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity
por: Scurr, Martin J., et al.
Publicado: (2022)

Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells
por: Ondondo, Beatrice, et al.
Publicado: (2013)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors
por: Colbeck, Emily J., et al.
Publicado: (2015)

Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(−) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells
por: Scurr, M, et al.
Publicado: (2014)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs
por: Yang, Ning, et al.
Publicado: (2023)

The Ussing chamber system for measuring intestinal permeability in health and disease
por: Thomson, Amanda, et al.
Publicado: (2019)

Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
por: Song, Guang-Yun, et al.
Publicado: (2011)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara
por: Jordan, Ingo, et al.
Publicado: (2009)

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
por: Frey, Sharon E., et al.
Publicado: (2015)

The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity
por: Milutinovic, Stefan, et al.
Publicado: (2021)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice
por: Bohnen, C, et al.
Publicado: (2013)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
por: Hebben, Matthias, et al.
Publicado: (2004)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
por: Kaufman, Howard L, et al.
Publicado: (2009)

Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion
por: Hughes, Ellyn, et al.
Publicado: (2020)

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies
por: Garber, David A., et al.
Publicado: (2009)

Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model
por: Nörder, Miriam, et al.
Publicado: (2010)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans
por: Capone, Stefania, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4d68gmonkh1bhdj7euqurhjmov